Showing results (111-120 of 215) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|November 2, 2021
Identification of patients at high risk of secondary extramedullary multiple myeloma developmentMartin Stork, Sabina Sevcikova, Jiri Minarik, et al.
Blood Cancer Journal|August 20, 2024
Haplotype analysis identifies functional elements in monoclonal gammopathy of unknown significanceHauke Thomsen, Subhayan Chattopadhyay, Niels Weinhold, et al.
European Journal of Haematology|May 10, 2016
Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significanceAneta Mikulasova, Jan Smetana, Marketa Wayhelova, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Ejhaem|July 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial)Heinz Ludwig, Bela Hausmann, Martin Schreder, et al.
Haematologica|July 16, 2026
Teclistamab in relapsed/refractory Waldenstro m macroglobulinemiaMichal Kascak, Ludmila Muronova, Ondrej Venglar, et al.
British Journal of Cancer|September 28, 2019
Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myelomaHeinz Ludwig, Wolfram Poenisch, Stefan Knop, et al.
Leukemia & Lymphoma|January 18, 2017
Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study GroupNorbert Grzasko, Roman Hajek, Marek Hus, et al.
Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.
BMC Cancer|April 9, 2025
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma GroupJiri Minarik, Ludek Pour, Vojtech Latal, et al.
Pageof 22